PRODUCT INFORMATION



DRB

Item No. 10010302

CAS Registry No.:	53-85-0	
Formal Name:	5,6-dichloro-1-β-D-ribofuranosyl-1H-	CI
	benzimidazole	
Synonyms:	Benzimidazole, NSC 401575	
MF:	C ₁₂ H ₁₂ Cl ₂ N ₂ O ₄	$\backslash _/$
FW:	319.1	
Purity:	≥98%	
UV/Vis.:	λ _{max} : 214 nm	HO Y Y
Supplied as:	A crystalline solid	<u>) </u>
Storage:	-20°C	но́он
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

DRB is supplied as a crystalline solid. A stock solution may be made by dissolving the DRB in the solvent of choice, which should be purged with an inert gas. DRB is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of DRB in ethanol is approximately 0.5 mg/ml and approximately 10 mg/ml in DMSO and DMF.

DRB is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, DRB should first be dissolved in DMF and then diluted with the aqueous buffer of choice. DRB has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

DRB is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II ($IC_{50} = 4-10 \ \mu M$)¹, cyclin-dependent kinase 7 (Cdk7) ($IC_{50} = ~20 \ \mu M$)^{2,3}, Cdk8 ($IC_{50} = ~20 \ \mu M$)³, and Cdk9 ($IC_{50} = 3 \ \mu M$).⁴ Through inhibition of certain CTD kinases, DRB inhibits an elongation step during RNA polymerase II transcription^{5,6}, which can trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells.⁷ DRB can also inhibit HIV transcription $(IC_{50} = -4 \mu M)$ by targeting elongation enhanced by the HIV-encoded transactivator Tat.⁸

References

- 1. Zandomeni, R.O. Biochem J. 262(2), 469-473 (1989).
- 2. Yankulov, K., Yamashita, K., Roy, R., et al. J. Biol. Chem. 270(41), 23922-23925 (1995).
- 3. Rickert, P., Corden, J.L., and Lees, E. Oncogene 18(4), 1093-1102 (1999).
- 4. Schang, L.M. J. Antimicrob. Chemother. 50(6), 779-792 (2002).
- 5. Zandomeni, R., Zandomeni, M.C., Shugar, D., et al. J. Biol. Chem. 261(7), 3414-3419 (1986).
- 6. Yamaguchi, Y., Wada, T., and Handa, H. Genes to Cells 3(1), 9-15 (1998).
- 7. te Poele, R.H., Okorokov, A.L., and Joel, S.P. Oncogene 18(42), 5765-5772 (1999).
- 8. Marciniak, R.A. and Sharp, P.A. EMBO J. 10(13), 4189-4196 (1991).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM